# Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Canonical URL: https://biopharmsignal.com/news/PSTV/plus-therapeutics-secures-national-coverage-agreement-with-elevance-health-for-cnsider-cerebrospinal-fluid-assay-for-metastatic-cns-cancer
Ticker: PSTV
Company: PLUS THERAPEUTICS, Inc.
Source: PLUS THERAPEUTICS, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.plustherapeutics.com
## Summary

HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering

## Article Body
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering
## Recent Company News
- 2026-06-30 11:30 EST — [Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding](https://biopharmsignal.com/news/PSTV/plus-therapeutics-provides-mid-year-business-update-including-corporate-rebrandi-b0939053) — Source: PLUS THERAPEUTICS, Inc.
- 2026-06-25 13:46 EST — [Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer](https://biopharmsignal.com/news/PSTV/plus-therapeutics-secures-national-coverage-agreement-with-elevance-health-for-cnsider-cerebrospinal-fluid-assay-for-metastatic-cns-cancer) — Source: PLUS THERAPEUTICS, Inc.
- 2026-06-25 13:46 EST — [Plus Therapeutics to Provide Business Update Call on June 30, 2026](https://biopharmsignal.com/news/PSTV/plus-therapeutics-to-provide-business-update-call-on-june-30-2026) — Source: PLUS THERAPEUTICS, Inc.
- 2026-06-25 13:46 EST — [Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnsider-diagnostics-clinical-laboratory) — Source: PLUS THERAPEUTICS, Inc.
- 2026-06-25 13:46 EST — [Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-cnside-diagnostic-platform-demonstrates-substantial-healthcare-cost-reduction-in-patients-with-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)